Locke Bryan
Associate Professor
Academic Appointment(s)
Medical College of Georgia
Department of Medicine: Hematology and Oncology
Bio
Internal Medicine Residency, University of Vermont
Chief Residency, University of Vermont
Hematology/Oncology Fellowship, Northwestern University, Chicago, IL. 2012-2015
- (706) 721-3056
- (706) 721-5566
- CN5333
Education
Certifications
-
Hematology
ABIM, 2015
-
Medical Oncology
ABIM, 2015
-
Internal Medicine
ABIM, 2012
-
PHY
GA Composite Medical Brd, 2015
-
Georgia Medical License
Georgia Composite Medical Board, 2015
Awards & Honors
-
MCG Faculty Exemplary Teaching Award
2020
-
MCG Faculty Exemplary Teaching Award
2019
-
MCG Faculty Exemplary Teaching Award
2018
-
AACR/ASCO Vail Workshop
Methods in Clinical Cancer Research, 2014
-
Appointee to American Society of Hematology Trainee Council
2014
Courses Taught Most Recent Academic Year
-
GMED 5000
Basic Clerkship GMED
-
RHON 5000
Hematology-Oncology
-
GMED 5012
Hematology/Oncology Extn.
-
RMED 5000
Medicine
-
MEDI 6110
Patient Centered Learning 1
-
GMED 5077
Ambulatory Adult Select
-
PHAS 5227
Hematology and Oncology
-
MEDI 6210
Patient Centered Learning 2
Teaching Interests
Diagnosis and Treatment of Hematologic Malignancies
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
B cell neoplasms
T cell and natural killer (NK) cell neoplasms
Precursor lymphoid neoplasms
Immunodeficiency-associated lymphoproliferative disorders
Viral mediated lymphomas
Immunotherapy
Novel therapeutics
Bone and marrow transplantation
Scholarship
Selected Recent Publications
- Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy., 2022
Journal Article, Academic Journal
- Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma., 2022
Journal Article, Academic Journal
- Update on the role of copanlisib in hematologic malignancies., 2021
Journal Article, Academic Journal
- Leukaemic relapse of anaplastic large cell lymphoma, ALK negative, 2021
Journal Article, Academic Journal
- Abstract CT240: A phase I clinical trial to study the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies, 2020
Conference Proceeding
Research Interests
Lymphomas
Immunotherapy
Novel Therapeutics
University Service
-
Appointee, Clinical Performance / Utilization Workgroup Augusta University Health System
2017 - Present
-
Member, Compliance / Audit / Ethics Committee AUMC
2017 - Present
-
Member, Peer Review Committee
2017 - Present
-
Member, Pharmacy and Therapeutics Committee
2017 - Present
